Catalyst Pharmaceuticals, Inc.
15
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
20.0%
3 terminated/withdrawn out of 15 trials
75.0%
-11.5% vs industry average
33%
5 trials in Phase 3/4
122%
11 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
Role: lead
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
Role: lead
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Role: lead
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Role: lead
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
Role: lead
Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
Role: collaborator
Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
Role: lead
A Safety, Tolerability and Pharmacokinetic Study of CPP-115
Role: lead
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Role: lead
Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence
Role: lead
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Role: lead
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Role: lead
Vigabatrin for the Treatment of Cocaine Dependency
Role: lead
Vigabatrin for Treatment of Cocaine Dependence
Role: lead
Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence
Role: collaborator
All 15 trials loaded